Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer.

Tumor inflitrating lymphocyte therapies are a promising type of cellular immunotherapy used to treat a broad range of solid malignant tumors.

CEL-SCI Corporation ("CEL-SCI" or the "Company") , a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced best-efforts offering of 16,000,000 shares of its ...

Researchers developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma - a ...

Dr. Peter Chen, radiation oncologist at Corewell Health William Beaumont University Hospital in Royal Oak, pledged $5 million ...

Shannin Desroches was diagnosed with stage 4 colon cancer. She had no symptoms for years, experiencing a nagging pain only ...

Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care.

SeaStar Medical has been selected to receive the 2025 Corporate Innovator Award from the National Kidney Foundation (NKF) at the 2025 Spring Clinical Meetings in ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Vets removed nine-year-old Calvin’s scapula — his shoulder blade —along with all traces of his tumor while keeping his leg ...